Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM01 versus epoetin beta for anaemia in non-dialysis chronic renal failure
2005-000140-85Phase 2Completed
- Sponsor
- BioGeneriX AG
- Start
- May 2005
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anemia of chronic kidney disease comparing XM01 subcutaneous with Epoetin beta subcutaneous (2 arms). Primary endpoints: Dose-dependent average increase of haemoglobin per week within the fixed dose phase and Statistical difference in haemoglobin increase between XM01 dose levels. Started May 2005; status: completed.
02
Drugs
epoetin thetaepoetin beta
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2005-000140-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000140-85.